XML 20 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
 [1]
Current assets:    
Cash and cash equivalents $ 183,179 $ 151,686
Short-term investments 241,094 268,117
Trade and other receivables 34,076 40,444
Inventory 3,304 3,338
Prepaid expenses and other current assets 6,297 5,416
Total current assets 467,950 469,001
Long-term investments 47,351 55,601
Long-term restricted cash and investments 4,150 4,150
Property and equipment, net 2,594 2,071
Goodwill 63,684 63,684
Other long-term assets 1,251 1,232
Total assets 586,980 595,739
Current liabilities:    
Accounts payable 4,649 6,565
Accrued compensation and benefits 14,490 20,334
Accrued clinical trial liabilities 14,478 14,131
Convertible notes 113,349 109,122
Term loan payable 0 80,000
Current portion of deferred revenue 30,662 19,665
Other current liabilities 24,659 18,969
Total current liabilities 202,287 268,786
Long-term portion of deferred revenue 261,236 237,094
Other long-term liabilities 3,707 541
Total liabilities 467,230 506,421
Commitments
Stockholders’ equity    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 292,302,330 and 289,923,798 at March 31, 2017 and December 31, 2016, respectively 292 290
Additional paid-in capital 2,086,483 2,072,591
Accumulated other comprehensive loss (326) (416)
Accumulated deficit (1,966,699) (1,983,147)
Total stockholders’ equity 119,750 89,318
Total liabilities and stockholders’ equity $ 586,980 $ 595,739
[1] The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.